NI201500031A - Métodos para tratar la enfermedad de alzheimer y composiciones farmacéuticas de los mismos. - Google Patents

Métodos para tratar la enfermedad de alzheimer y composiciones farmacéuticas de los mismos.

Info

Publication number
NI201500031A
NI201500031A NI201500031A NI201500031A NI201500031A NI 201500031 A NI201500031 A NI 201500031A NI 201500031 A NI201500031 A NI 201500031A NI 201500031 A NI201500031 A NI 201500031A NI 201500031 A NI201500031 A NI 201500031A
Authority
NI
Nicaragua
Prior art keywords
methods
disease
same
pharmaceutical compositions
treat alzheimer
Prior art date
Application number
NI201500031A
Other languages
English (en)
Inventor
Schmidt Ellen
Areberg Johan
Original Assignee
H Lundbeck As
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=49118521&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NI201500031(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by H Lundbeck As filed Critical H Lundbeck As
Publication of NI201500031A publication Critical patent/NI201500031A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A61K31/4045—Indole-alkylamines; Amides thereof, e.g. serotonin, melatonin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/27—Esters, e.g. nitroglycerine, selenocyanates of carbamic or thiocarbamic acids, meprobamate, carbachol, neostigmine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Abstract

La presente invención describe métodos para tratar demencia que comprenden administrar una dosis diaria eficaz de N-(2-(6-fluoro-1H-indol-3-il)etil)-3-(2,2,3,3-tetrafluoropropoxi)bencilamina para mejorar o aumentar el efecto de un inhibidor de la acetilcolinesterasa.
NI201500031A 2012-09-09 2015-03-06 Métodos para tratar la enfermedad de alzheimer y composiciones farmacéuticas de los mismos. NI201500031A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201261698664P 2012-09-09 2012-09-09
US201361782084P 2013-03-14 2013-03-14

Publications (1)

Publication Number Publication Date
NI201500031A true NI201500031A (es) 2016-02-15

Family

ID=49118521

Family Applications (1)

Application Number Title Priority Date Filing Date
NI201500031A NI201500031A (es) 2012-09-09 2015-03-06 Métodos para tratar la enfermedad de alzheimer y composiciones farmacéuticas de los mismos.

Country Status (33)

Country Link
US (4) US9375418B2 (es)
EP (1) EP2892563B1 (es)
JP (2) JP6693744B2 (es)
KR (2) KR20150065680A (es)
CN (1) CN104619344A (es)
AP (1) AP2015008306A0 (es)
AU (1) AU2013311573B2 (es)
BR (1) BR112015005117B1 (es)
CA (1) CA2883751C (es)
CL (1) CL2015000578A1 (es)
CY (1) CY1121062T1 (es)
DK (1) DK2892563T3 (es)
EA (1) EA030448B1 (es)
ES (1) ES2703630T3 (es)
GE (1) GEP201706776B (es)
HK (1) HK1212217A1 (es)
HR (1) HRP20182069T1 (es)
IL (1) IL237369B (es)
JO (1) JO3459B1 (es)
LT (1) LT2892563T (es)
MX (1) MX368305B (es)
MY (1) MY182539A (es)
NI (1) NI201500031A (es)
NZ (1) NZ630589A (es)
PL (1) PL2892563T3 (es)
PT (1) PT2892563T (es)
RS (1) RS58104B1 (es)
RU (1) RU2675786C2 (es)
SG (1) SG11201501774QA (es)
SI (1) SI2892563T1 (es)
TN (1) TN2015000076A1 (es)
TW (1) TWI632909B (es)
WO (1) WO2014037532A1 (es)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE602004000260T2 (de) 2003-07-22 2006-08-24 Arena Pharmaceuticals, Inc., San Diego Diaryl- und arylheteroarylharnstoffderivate als modulatoren des 5-ht2a-serotoninrezeptors, die sich zur prophylaxe und behandlung von damit im zusammenhang stehenden erkrankungen eignen
EP2508177A1 (en) 2007-12-12 2012-10-10 Glaxo Group Limited Combinations comprising 3-phenylsulfonyl-8-piperazinyl-1yl-quinoline
US20110021538A1 (en) 2008-04-02 2011-01-27 Arena Pharmaceuticals, Inc. Processes for the preparation of pyrazole derivatives useful as modulators of the 5-ht2a serotonin receptor
WO2010062321A1 (en) 2008-10-28 2010-06-03 Arena Pharmaceuticals, Inc. Processes useful for the preparation of 1-[3-(4-bromo-2-methyl-2h-pyrazol-3-yl)-4-methoxy-phenyl]-3-(2,4-difluoro-phenyl)-urea and crystalline forms related thereto
JO3459B1 (ar) 2012-09-09 2020-07-05 H Lundbeck As تركيبات صيدلانية لعلاج مرض الزهايمر
JO3773B1 (ar) 2013-03-14 2021-01-31 Janssen Pharmaceutica Nv معدلات p2x7
TWI627174B (zh) 2013-03-14 2018-06-21 比利時商健生藥品公司 Ｐ２ｘ７調控劑
NZ710034A (en) 2013-03-14 2020-06-26 Boehringer Ingelheim Int Substituted 2-aza-bicyclo[2.2.1]heptane-3-carboxylic acid (benzyl-cyano-methyl)-amides inhibitors of cathepsin c
WO2014152537A1 (en) 2013-03-14 2014-09-25 Janssen Pharmaceutica Nv P2x7 modulators
EP2970271B1 (en) 2013-03-14 2017-11-08 Janssen Pharmaceutica NV P2x7 modulators
JO3639B1 (ar) * 2014-07-04 2020-08-27 H Lundbeck As صورة متعددة الشكل جديدة لـ n-[2-(6-فلورو-1h-إندول-3-يل)إيثيل]-3-(2،2،3،3-تترا فلورو بروبوكسي)بنزيل أمين هيدروكلوريد
ES2714048T3 (es) 2014-09-12 2019-05-24 Janssen Pharmaceutica Nv Moduladores de P2X7
KR102510588B1 (ko) 2014-09-12 2023-03-17 베링거 인겔하임 인터내셔날 게엠베하 카텝신 c의 스피로사이클릭 억제제
CN105175307A (zh) * 2014-11-18 2015-12-23 苏州晶云药物科技有限公司 Lu AE58054的盐酸盐晶型A及其制备方法和用途
WO2016179569A1 (en) * 2015-05-07 2016-11-10 Axovant Sciences Ltd. Compositions and methods of treating a neurodegenerative disease
JP2018516992A (ja) 2015-06-12 2018-06-28 アクソファント サイエンシーズ ゲーエムベーハーＡｘｏｖａｎｔ Ｓｃｉｅｎｃｅｓ Ｇｍｂｈ レム睡眠行動障害の予防および処置のために有用なジアリールおよびアリールヘテロアリール尿素誘導体
RU2018103338A (ru) 2015-07-15 2019-08-15 Аксовант Сайенсиз Гмбх Производные диарил- и арилгетероарилмочевины для профилактики и лечения галлюцинаций, ассоциированных с нейродегенеративным заболеванием
DK3448430T3 (da) * 2016-04-26 2023-07-03 H Lundbeck As Anvendelse af en acetylcholinesterase-inhibitor og idalopirdin til reduktion af fald hos patienter med parkinsons sygdom
US10864191B2 (en) * 2016-05-11 2020-12-15 H. Lundbeck A/S 5-HT6 receptor antagonists for use in the treatment of Alzheimer's disease with apathy as comorbidity
RS60422B1 (sr) 2016-05-18 2020-07-31 Suven Life Sciences Ltd Kombinacija čistih antagonista 5-ht6 receptora sa inhibitorima acetilholinesteraze
CN106309436A (zh) * 2016-07-25 2017-01-11 宁波大学 可用作乙酰胆碱酯酶抑制剂的色胺衍生物及其用途
CN107118146B (zh) * 2017-04-13 2019-09-03 宁波大学 一种6-溴色胺衍生物及其制备方法和用途
BR112019001145A2 (pt) * 2017-05-24 2019-04-30 H. Lundbeck A/S combinação de um antagonista do receptor 5-ht6 e de um inibidor de acetilcolinesterase para uso no tratamento da doença de alzheimer em uma subpopulação de pacientes portadores de alelos de apoe4
EP3856179A1 (en) 2018-09-28 2021-08-04 Janssen Pharmaceutica N.V. Monoacylglycerol lipase modulators
EP3856178A1 (en) 2018-09-28 2021-08-04 Janssen Pharmaceutica NV Monoacylglycerol lipase modulators
US11839663B2 (en) 2019-09-30 2023-12-12 Janssen Pharmaceutica Nv Radiolabelled MGL pet ligands
NL2024431B1 (en) 2019-12-11 2021-09-07 Sulfateq Bv Compounds for treatment of alzheimer’s disease
JP2023518511A (ja) 2020-03-26 2023-05-01 ヤンセン ファーマシューティカ エヌ．ベー． モノアシルグリセロールリパーゼ調節因子

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3597149A (en) 1969-04-29 1971-08-03 Showa Denko Kk Inhibition of gas-fume fading of dyed cellulose acetate material
FR2181559A1 (en) 1972-04-28 1973-12-07 Aec Chimie Organique Bio N-Phenylalkyl-N-3-indolylalkyl-alkylamines - with sedative, neuroleptic, analgesic, hypotensive, antiserotonin, adrenolytic activity
JPS5764632A (en) 1980-10-09 1982-04-19 Mitsui Toatsu Chem Inc Novel 2-arylethyl ether derivative and thioether derivative, their production and insecticide and acaricide
US5202336A (en) 1986-09-24 1993-04-13 Bayer Aktiengesellschaft Antiflammatory quinolin methoxy phenylsulphonamides
DE3632329A1 (de) 1986-09-24 1988-03-31 Bayer Ag Substituierte phenylsulfonamide
SE9103745D0 (sv) 1991-12-18 1991-12-18 Wikstroem Haakan Aryl-triflates and related compounds
DE69411143T2 (de) 1993-09-01 1998-10-22 Allelix Biopharma Tryptamin analoge mit 5-ht1d selektivität
US5504101A (en) 1994-05-06 1996-04-02 Allelix Biopharmaceuticals, Inc. 5-HT-1D receptor ligands
DK1032559T3 (da) 1997-09-29 2007-02-26 Aventis Pharma Inc Aminoalkylphenolderivater til behandling af depression og hukommelsessvigt
GB9820113D0 (en) 1998-09-15 1998-11-11 Merck Sharp & Dohme Therapeutic agents
WO2000034242A1 (en) 1998-12-11 2000-06-15 Virginia Commonwealth University Selective 5-ht6 receptor ligands
BR9916905A (pt) 1999-01-13 2002-01-29 Millennium Pharm Inc Composto, composição farmacêutica, métodos para modular a atividade de um receptor de quimiocina, para prevenir infecção por hiv, tratar infecção por hiv, retardar o ìnicio de aids, ou tratar aids e para tratar uma doença inflamatória, e, combinação
US6750348B1 (en) 1999-03-24 2004-06-15 Anormed, Inc. Chemokine receptor binding heterocyclic compounds
AU2002303094B2 (en) * 2001-03-29 2006-11-23 Eli Lilly And Company N-(2-arylethyl)benzylamines as antagonists of the 5-HT6 receptor
RU2252936C2 (ru) * 2002-12-05 2005-05-27 Институт физиологически активных веществ РАН S-замещенные n-1-[(гетеро)арил]алкил-n`-[(гетеро)арил]алкилизотиомочевины, способ их получения, фармацевтическая композиция, способ изучения глутаматэргической системы, способы лечения (варианты)
PE20071143A1 (es) 2006-01-13 2008-01-20 Wyeth Corp Composicion farmaceutica que comprende un inhibidor de acetilcolinesterasa y un antagonista 5-hidroxitriptamina-6
US20100120747A1 (en) 2006-06-23 2010-05-13 Laboratorios Del Dr. Esteve, S.A. Combination of a cholinesterase inhibitor and a compound with 5-ht6 receptor affinity
AR061637A1 (es) 2006-06-26 2008-09-10 Epix Delaware Inc Composiciones y metodos de tratamiento de trastornos del snc
CA2768668A1 (en) * 2009-07-23 2011-01-27 Shire Llc Galantamine amino acid and peptide prodrugs and uses thereof
TW201139370A (en) 2009-12-23 2011-11-16 Lundbeck & Co As H Processes for the manufacture of a pharmaceutically active agent
JO3459B1 (ar) * 2012-09-09 2020-07-05 H Lundbeck As تركيبات صيدلانية لعلاج مرض الزهايمر

Also Published As

Publication number Publication date
DK2892563T3 (en) 2019-01-21
ES2703630T3 (es) 2019-03-11
RU2675786C2 (ru) 2018-12-25
EA030448B1 (ru) 2018-08-31
KR20200137028A (ko) 2020-12-08
MY182539A (en) 2021-01-25
JP2015528471A (ja) 2015-09-28
US9789085B2 (en) 2017-10-17
AU2013311573B2 (en) 2017-10-12
BR112015005117B1 (pt) 2022-06-21
US20160256437A1 (en) 2016-09-08
EA201590353A1 (ru) 2016-03-31
IL237369A0 (en) 2015-04-30
TN2015000076A1 (en) 2016-06-29
CL2015000578A1 (es) 2015-05-15
BR112015005117A2 (pt) 2017-07-04
JO3459B1 (ar) 2020-07-05
TW201414474A (zh) 2014-04-16
SI2892563T1 (sl) 2019-02-28
PL2892563T3 (pl) 2019-04-30
AP2015008306A0 (en) 2015-03-31
KR20150065680A (ko) 2015-06-15
MX368305B (es) 2019-09-27
US10660878B2 (en) 2020-05-26
US9687473B2 (en) 2017-06-27
KR102342127B1 (ko) 2021-12-21
MX2015002879A (es) 2015-07-06
EP2892563B1 (en) 2018-11-14
SG11201501774QA (en) 2015-05-28
JP2019059760A (ja) 2019-04-18
CY1121062T1 (el) 2019-12-11
CA2883751A1 (en) 2014-03-13
RU2015107877A (ru) 2016-10-27
US20140073681A1 (en) 2014-03-13
US9375418B2 (en) 2016-06-28
CN104619344A (zh) 2015-05-13
TWI632909B (zh) 2018-08-21
CA2883751C (en) 2020-11-24
HRP20182069T1 (hr) 2019-02-08
AU2013311573A1 (en) 2015-03-12
HK1212217A1 (en) 2016-06-10
IL237369B (en) 2018-11-29
US20180071254A1 (en) 2018-03-15
EP2892563A1 (en) 2015-07-15
AU2013311573A8 (en) 2015-03-19
LT2892563T (lt) 2019-01-10
NZ630589A (en) 2015-12-24
PT2892563T (pt) 2019-01-10
WO2014037532A1 (en) 2014-03-13
RS58104B1 (sr) 2019-02-28
JP6693744B2 (ja) 2020-05-13
GEP201706776B (en) 2017-11-27
US20160354343A1 (en) 2016-12-08

Similar Documents

Publication Publication Date Title
NI201500031A (es) Métodos para tratar la enfermedad de alzheimer y composiciones farmacéuticas de los mismos.
CO2017004481A2 (es) Compuestos de indol carboxamida utiles como inhibidores de cinasas
ECSP16072941A (es) 2-amino-3,5,5-trifluoro-3,4,5,6-tetrahidropiridinas como inhibidores de bace1 para el tratamiento de la enfermedad de alzheimer
NI201600165A (es) Inhibidores de desmetilasa 1 específica a lisina
NZ730808A (en) Immunoregulatory agents
NI201700056A (es) 2-amino-3,5-difluoro-6-metil-6-fenil-3,4,5,6-tetrahidropiridinas en calidad de inhibidores de bace1 para el tratamiento de la enfermedad de alzhéimer
EA201590450A1 (ru) Сульфамоил-ариламиды и их применение в качестве лекарственных препаратов для лечения гепатита b
EA201892219A1 (ru) Замещенные производные индолина в качестве ингибиторов репликации вирусов денге
EA201892216A1 (ru) Замещенные производные индолина в качестве ингибиторов репликации вирусов денге
BR112015022643A2 (pt) inibidores diidro-pirrolpiridinona
EA201892200A1 (ru) Замещенные производные соединений индола в качестве ингибиторов репликации вирусов денге
EA201790700A1 (ru) Моно- или дизамещенные индолы в качестве ингибиторов репликации вирусов денге
PH12017500841A1 (en) 2-amino-6-(difluoromethyl)- 5,5-difluoro-6-phenyl-3,4,5,6-tetrahydropyridines as bace1 inhibitors
EA201791259A1 (ru) Производные пиперидина в качестве ингибиторов hdac1/2
CR20190361A (es) Dendrímeros terapéuticos
BR112015020139A2 (pt) compostos terapêuticos e usos dos mesmos
PH12015502365A1 (en) Bace1 inhibitors
EA201790315A1 (ru) Модуляторы x-рецепторов печени
BR112018073419A2 (pt) combinação, uso da combinação, método para o tratamento, composto, método para o tratamento de doença de alzheimer e composição farmacêutica
CL2017002229A1 (es) Inhibidores de bace1.
MX2016008968A (es) Compuestos organicos.
AR105400A1 (es) Inhibidores de jak1
NZ727251A (en) Novel polymorphic form of n-[2-(6-fluoro-1h-indol-3-yl)ethyl]-3-(2,2,3,3-tetrafluoropropoxy)benzylamine hydrochloride for the treatment of alzheimer’s
UA123899U (uk) Застосування солей тіазолію як агентів, що інгібують активність ацетилхолінестерази і бутирилхолінестерази
TH167631B (th) วิธีการบำบัดโรคอัลไซเมอร์และองค์ประกอบทางเภสัชกรรมของมัน